To determine the relationship between proton magnetic resonance spectroscopy ( 1 H MRS) metabolites and ␤-amyloid (A␤) load and the effects of A␤ load on the association between 1 H MRS metabolites and cognitive function in cognitively normal older adults.
Up to 30% of cognitively normal older adults have increased ␤-amyloid (A␤) deposition on PET imaging with amyloid ligand 11 C-Pittsburgh compound B (PiB). 7 Understanding the relationship between A␤ load and 1 H MRS abnormalities in cognitively normal older adults may give insights on the biologic basis of 1 H MRS metabolite changes in early AD. We hypothesized that 1 H MRS metabolite abnormalities are associated with cognitive function in cognitively normal older adults and that preclinical AD pathology is responsible for this association. In a population-based cohort of cognitively normal older adults, our primary objective was to determine the association between 1 H MRS metabolite markers and A␤ load. Our secondary objective was to determine the association between 1 H MRS markers and cognitive per-formance and whether A␤ load modifies this association.
METHODS Participants. We studied 311 cognitively normal older adults who participated in the population-based Mayo Clinic Study of Aging (MCSA) from January 2009 through September 2010. MCSA is a prospective population-based study of older adults without dementia. 8 Individuals participating in the MCSA undergo clinical examinations, a battery of neuropsychological tests, and MRI/MRS examinations every 15 months. After completion of each evaluation, a consensus committee meeting is held involving the behavioral neurologists, neuropsychologists, and nurses who evaluated the subjects to assign a clinical diagnosis to the participant. PET studies have been offered to all MCSA participants since January 2009 and are performed within 6 months of the MRI/MRS and cognitive testing.
Normal cognitive function was judged according to the published criteria, 9 and the cognitively normal subjects received a Clinical Dementia Rating of 0. Subjects who had a contraindication for MRI, such as a pacemaker, or who were unable to participate in imaging studies because of severe illness were excluded. Subjects were not excluded due to neurologic, psychiatric, or systemic illnesses to preserve the representativeness of the study sample.
Standard protocol approvals, registrations, and patient consents. This study was approved by the Mayo Clinic Institutional Review Board, and informed consent for participation was obtained from every subject. Neuropsychological testing. Memory was evaluated by 30minute delayed free recall scores for the Wechsler Memory Scale-Revised Logical Memory and Visual Reproduction subtests and also for the Rey Auditory Verbal Learning Test (AVLT). Language tests measured naming to confrontation with the Boston Naming Test and category fluency (i.e., naming animals, fruits, and vegetables). Attention/executive measures included the Trail Making Test Part B and the Wechsler Adult Intelligence Scale-Revised (WAIS-R) Digit Symbol subtest. Visual-spatial processing was examined by the WAIS-R Picture Completion and Block Design subtests. All tests were administered by experienced psychometrists and supervised by a clinical neuropsychologist.
MRI and 1 H MRS. MRI and single voxel (SV) 1 H MRS
examinations were performed at 3 T using an 8-channel phased array coil (GE Healthcare). A 3-dimensional high-resolution magnetization-prepared rapid gradient echo (MPRAGE) acquisition with repetition time/echo time/inversion time ϭ 7/3/900 msec, flip angle 8 degrees, in-plane resolution of 1.0 mm, and a slice thickness of 1.2 mm was performed for anatomic segmentation and labeling of PiB PET scans and 1 H MRS voxel localization. 1 H MRS studies were performed using the automated MRS package Proton Brain Examination/SV. A point-resolved spectroscopy sequence with repetition time ϭ 2,000, echo time ϭ 30 msec, 2,048 data points, and 128 excitations was used for the examinations. 10 An 8-cm 3 (2 ϫ 2 ϫ 2 cm) 1 H MRS voxel was prescribed on a midsagittal MPRAGE image, including right and left posterior cingulate gyri. 3 Metabolite intensity ratios calculated at the end of each PROBE/SV acquisition were analyzed. Quantifying metabolite intensities by referencing to an internal standard is preferred in clinical 1 H MRS, because internal referencing does not require correction for coil loading, atrophy, and relaxation times and can readily be used in clinical practice with standard equipment and vendor-provided processing software.
PiB PET. PET images were acquired using a PET/CT scanner (DRX, GE Healthcare) operating in 3-dimensional mode. The subjects were injected with 292-729 MBq 11 C-PiB. A CT image was obtained for attenuation correction. After a 40-minute uptake period, a 20-minute PiB scan was obtained. The PiB PET acquisition consisted of 4 5-minute dynamic frames, acquired from 40 to 60 minutes after injection. Standard corrections were applied. The pixel size for PET images was 1.0 mm, and the slice thickness was 3.3 mm. PiB PET quantitative image analysis was performed using the fully automated image processing pipeline as described in detail previously. 11 In brief, the method includes gray matter (GM) sharpening of PET images using MRI and partial volume correction of CSF and tissue compartments using statistical parametric mapping 5. PiB PET cortical ratio images were calculated by dividing each PiB PET GM voxel value by the median value in the cerebellar GM region in the patient's MRI space. The global cortical PiB retention was calculated by taking the median value of the PiB PET GM ratio from the bilateral parietal, posterior cingulate, precuneus, temporal, prefrontal, orbitofrontal, and anterior cingulate GM regions in the in-house modified anatomic labeling atlas. 11, 12 Statistical analysis. We summarize associations between numeric variables using Spearman partial rank order correlations, which we denote by partial r s . 13 This statistic can be thought of as a nonparametric correlation between 2 variables (e.g., PiB and Cho/Cr) after partialling out, or controlling for, possible confounders. For testing associations involving MRS and PiB, we control for age and sex. In testing associations involving neuropsychological variables, we control for age, sex, and years of education. We used rank sum tests for between-group comparisons and partial r s to quantify associations because some neuropsychological variables were found to be highly non-normal with skewness and floor or ceiling effects, and the PiB distributions were highly skewed and possibly bimodal. In simulation studies, this statistic was found to perform well with highly non-normal data. 13 As with other correlation measures, partial r s values are bounded between Ϫ1 and ϩ1. A general interpretation of partial r s is that significant values indicate that as values in one variable increase, values in the other variable tend to increase (or decrease), after controlling for possible confounders. To estimate and test differences in partial r s between subjects found to have global PiB Ͻ1.5 vs those found to have global PiB Ն1. . The only exception was that the fraction of female participants was slightly less than the fraction of female nonparticipants. The cognitive performance of the participants was similar to that of the nonparticipants on neuropsychometric tests; however, the participants on average performed a few points better on tests that assessed memory, visualspatial function, and attention/executive function.
Correlations between A␤ load and 1 H MRS metabolites.
Statistical summaries of 1 H MRS metabolite ratios in the whole sample of PET/MRS study participants and in participants with low (Ͻ1.5) and high (Ն1.5) PiB retention are listed in table 2. The 1 H MRS metabolite ratios that correlated with the global cortical PiB uptake ratio were mI/Cr (Spearman partial r s ϭ 0.17; p ϭ 0.003) and Cho/Cr (Spearman partial r s ϭ 0.13; p ϭ 0.03) after adjusting for age and sex. Although NAA/Cr levels decreased with increasing PiB retention, there was no association between neuronal marker NAA/Cr and global cortical PiB retention (Spearman partial r s ϭ Ϫ0.07; p ϭ 0.24). Because 1 H MRS metabolite ratios were acquired from the posterior cingulate gyrus, we also tested the associations between 1 H MRS metabolite ratios and cortical PiB retention in the posterior cingulate gyrus.
The strength of the associations with mI/Cr (Spearman partial r s ϭ 0.15; p ϭ 0.007) and Cho/Cr (Spearman partial r s ϭ 0.15; p ϭ 0.01) was similar to that of the associations we found with the global cortical PiB retention after adjustment for age and sex (figure 1).
Correlations between 1 H MRS and cognition and the
effect of A␤ load on these correlations. Among the 3 metabolite ratios, only Cho/Cr correlated with cognitive function after adjustment for age, sex, and ed- We observed high levels of PiB retention (Ն1.5 global cortical retention ratio) in 33% of the cognitively normal individuals at or older than 70 years. This is on a par with the 20%-30% rate of high cortical PiB retention ratio that we and others have reported in the literature 7, 11, 14, 15 but lower than the 47% rate reported in the AD Neuroimaging Initiative cognitively normal cohort. 16 The differences are most likely due to the methods of subject ascertain- ment and recruitment. In the current study, we recruited subjects who had been randomly selected from the Olmsted County population. This is in contrast to the previously studied cohorts of cognitively normal volunteers recruited through advertisements or memory clinics, 7, 11, 14, 15 which increases the potential for selection or volunteer bias. Although it is possible that people with poor general health would be less likely to participate in imaging studies, we did not exclude subjects due to neurologic, psychiatric, or systemic illnesses to study a representative sample of the population. The cognitive function in participants and nonparticipants in the randomly sampled population was on average similar, although participants performed a few points better on tests that assessed memory, visual-spatial function, and attention/executive function, suggesting minimal nonparticipation bias, if any. Although 1 H MRS metabolite ratios were measured from the posterior cingulate gyri, both global cortical PiB retention and posterior cingulate gyri PiB retention similarly correlated with the 1 H MRS metabolite levels. This result is expected given that the regional variability of PiB retention in cognitively normal individuals is typically low among regions that are included in the global cortical PiB retention ratio (i.e., posterior cingulate gyri and temporal, parietal, and frontal lobe association cortices). 11, 14 In Spearman partial correlations between choline (Cho)/creatine (Cr) and cognitive performance
Black circles indicate partial r s in the whole sample of PET/magnetic resonance spectroscopy study participants, blue squares indicate the partial r s in participants with low 11 C-Pittsburgh compound B (PiB) retention, and red triangles indicate the partial r s in participants with high PiB retention. The gray lines are the confidence intervals. For the Trail Making Test Part B, a higher score indicates worse performance. For all other neuropsychometric tests, a lower score indicates worse performance. A higher Cho/Cr ratio was associated with worse performance on Rey Auditory Verbal Learning Test (AVLT) Delayed Recall (p ϭ 0.04), Trail Making Test Part B (p ϭ 0.04), Wechsler Adult Intelligence Scale-Revised (WAIS-R) Digit Symbol (p ϭ 0.001), and WAIS-R Block Design (p ϭ 0.03) after adjustment for age, sex, and education. However, we did not find any evidence that the Spearman partial r s values between Cho/Cr and neuropsychological scores were significantly different between participants with high vs low PiB retention (table e-1).
our sample, we found a modest correlation between PiB retention and both mI/Cr and Cho/Cr. However, in an earlier imaging-autopsy correlation study, only antemortem mI/Cr levels correlated with the density of neuritic plaques in subjects at autopsy, who spanned the cognitive spectrum. 2 Therefore, mechanisms underlying the association between PiB retention and mI/Cr are likely to be different from the mechanisms underlying the association between PiB retention and Cho/Cr. 1 H MRS findings in patients with MCI 3,17,18 and mild AD 19 and in presymptomatic carriers of the familial AD mutations 5 suggest that mI/Cr elevation is an early event in the progression of AD pathology. The mI peak consists of glial metabolites that are responsible for osmoregulation. 20 -23 mI/Cr levels increase with age in the APP-PS1 mouse model of AD, coinciding with the timing of microglial activation in these mice. 24 It is thought that the elevation of the mI peak is related to glial proliferation and astrocytic and microglial activation in AD. 25 In the human brain, PiB labels both dense core and diffuse plaques, although labeling of diffuse plaques is less prominent than that of compact/cored plaques. 26 -28 Although most of the amyloid deposits in cognitively normal individuals are noncompact or diffuse and display only minimal glial reaction, the dense cored amyloid deposits in AD are surrounded by clusters of microglia and astrocytes. 29 If mI/Cr is a marker of astrocytic and microglial activation associated with the amyloid pathology of AD, then the association we observed between mI/Cr levels and PiB retention may be directly related to the presence of compact/ cored A␤ plaques. Based on this, we might expect to find an association between higher mI/Cr and worse cognitive performance. The absence of this expected correlation requires further investigation.
The only 1 H MRS marker that significantly correlated with cognitive function in cognitively normal older adults specifically in the attention/executive, memory, and visual-spatial function domains was Cho/Cr ratio. This is in agreement with a previous population-based study showing that Cho/Cr levels predict future cognitive decline in cognitively normal adults. 6 The biologic significance of Cho/Cr elevation in patients with AD and in patients with mild cognitive impairment is not fully understood. 30 The Cho peak is composed of cytosolic glycerophosphocholine and phosphocholine, which are the products of membrane phosphatidylcholine breakdown and precursors of choline and acetylcholine synthesis. 31 One possible explanation for the elevation of Cho in AD is increased membrane turnover due to neurodegeneration. It has also been hypothesized that the elevation of the Cho peak is the consequence of membrane phosphatidylcholine catabolism to provide free choline for the chronically deficient acetylcholine production in AD. 32, 33 Elevated Cho/Cr levels in patients with dementia with Lewy bodies characterized by a profound cholinergic deficit further support the hypothesis that elevation in Cho/Cr may be associated with cholinergic dysfunction. 34 Cho/Cr levels decrease with cholinergic agonist treatment in AD, suggesting that downregulation of choline acetyltransferase activity may be responsible for the elevation of Cho. 35 If indeed there is a relationship between Cho/Cr and cholinergic function in cognitively normal older adults, then Cho/Cr would be a potential biomarker for the cholinergic response in preclinical AD.
We did not find a correlation between NAA/Cr and cognitive function, nor did we find a significant correlation between NAA/Cr and A␤ load in cognitively normal older adults. Although the neuronal integrity marker NAA/Cr level is associated with cognitive function in patients with AD, 36, 37 both cross-sectional and longitudinal studies in patients with amnestic MCI and AD suggest that the elevation in mI/Cr and Cho/Cr precedes the decline in NAA/Cr in the temporal sequence of 1 H MRS changes in AD. 30, 38 Although NAA/Cr gradually declines in the course of AD starting from the amnestic MCI stage, NAA/Cr levels have been relatively stable in cognitively normal older adults during longitudinal studies in different cohorts. 39, 40 The relative stability of NAA/Cr in cognitively normal older adults suggests that the decline in NAA/Cr is associated with a diagnosis of amnestic MCI or AD but is not a significant feature of the preclinical disease process. The lack of an association between NAA/Cr and cognitive function in the cognitively normal subjects of this study agrees with this hypothesis.
Although the associations between 1 H MRS metabolites and A␤ pathology are modest, our data give insights on the significance of 1 H MRS metabolite markers in cognitively normal older adults. Our data showed that Cho/Cr level was associated with cognitive function independent of PiB retention. Cho/Cr correlated with WAIS-R Digit Symbol scores even in participants with low PiB retention, suggesting that the elevation of Cho/Cr is dependent on other pathophysiologic mechanisms characterized by elevated Cho/Cr levels in addition to A␤ pathology. These mechanisms may be increased membrane turnover due to preclinical vascular disease 6 or cholinergic dysfunction due to preclinical Lewy body disease. 34 Longitudinal follow-up and postmortem pathologic confirmation may further clarify the underpinnings of MRS metabolite changes in cognitively normal older adults.
